Research
Research
While NTSAD-DV is primarily an education and screening organization, we remain hopeful and supportive that science will continue to advance, providing a cure for Tay-Sachs, Canavan and other recessive genetic conditions. There are several patient advocacy organizations actively supporting research in these areas including:
This table highlights the major scientific approaches being explored for Tay‑Sachs disease and Canavan disease, showing where the research overlaps and where it diverges.
| Research Area | Tay-Sachs Disease | Canavan Disease |
|---|---|---|
| Cause | Mutation in HEXA → deficiency of hexosaminidase A → buildup of GM2 ganglioside Neurons (gray matter) | Mutation in ASPA → deficiency of aspartoacylase → buildup of N‑acetylaspartate (NAA) Myelin (white matter) |
| Main Tissue Affected | Neurons (gray matter) | Myelin (white matter) |
| Gene Therapy Research | AAV vectors delivering HEXA; dual‑vector systems to deliver both enzyme subunits; promising animal results | AAV‑ASPA gene therapy is the most advanced; human trials already conducted; reduces NAA and improves myelination |
| Stem Cell Therapy | Goal: provide cells that produce hexosaminidase A; challenges with engraftment and distribution | Goal: repair myelin and supply ASPA‑producing cells; some early improvements seen |
| Substrate Reduction Therapy (SRT) | Small molecules to reduce GM2 production; limited clinical benefit so far | Small molecules to reduce NAA or protect myelin; early‑stage research |
| Diagnostic Advances | Expanded carrier screening; improved genetic testing | MRI spectroscopy detects elevated NAA; improved newborn genetic screening |
| Clinical Trial Activity | Multiple preclinical and early‑phase gene therapy studies | Several gene therapy trials already completed; ongoing optimization |
| Overall Research Momentum | Rapid growth due to gene therapy advances | Strong momentum; Canavan is one of the earliest leukodystrophies targeted by gene therapy |
NTSAD-DV, with support from the Alison Ossip Fund, and the Ron and Joy Paul Family Foundation recently provided support to a truly groundbreaking study on a new treatment for Canavan Disease was recently published in Nature Medicine.[1] The peer-reviewed study reports on the early results of an open clinical trial using targeted gene therapy to restore myelin.
Like Tay-Sachs Disease, Canavan is an autosomal recessive disease. It is caused when a person inherits both copies of the ASPA gene in each cell that has mutations. The ASPA gene provides instructions for producing an enzyme called aspartoacylase, which is essential for breaking down N-acetylaspartic acid (NAA) in the brain. When the ASPA enzyme is deficient or nonfunctional due to genetic mutations, NAA cannot be properly metabolized. This leads to its accumulation in the brain, which disrupts the formation and maintenance of myelin, the protective sheath around nerve fibers. The progressive destruction of myelin sheaths impairs the ability of nerve cells to send and receive signals effectively. This results in the neurological symptoms characteristic of Canavan disease, such as developmental delays, muscle tone abnormalities, and macrocephaly (enlarged head).
A new clinical trial sponsored by Myrtelle Inc. being led locally by Rowan-Virtua School of Osteopathic Medicine researcher Paola Leone, Ph.D. is using targeted gene therapy to restore myelin, the brain’s protective coating, in children with Canavan disease. Early results show improved brain development and reduced toxic buildup. This new gene therapy (rAAV-Olig001-ASPA) is the first designed to target the oligodendrocytes. Oligodendrocytes are specialized glial cells in the central nervous system (CNS) that produce the myelin sheath.
The researchers believe that if they can produce the reconstitution of ASPA function in oligodendrocytes of the brains of Canavan patients, it will allow for NAA metabolism and support myelination/remyelination by the white matter producing cells. Researchers believe targeting oligodendrocytes offers the safest and most direct therapy for affected individuals.
According to clinicaltrials.gov, this study is a Phase 1/2 First-In-Human protocol designed to obtain safety, pharmacodynamics, and efficacy data following neurosurgical administration of a single dose of rAAV-Olig001-ASPA delivered intracerebroventricularly in up to 24 children with Canavan Disease.
If their research continues to show such promising results, the potential reaches far beyond Canavan disease. Oligodendrocytes are vital components of the central nervous system, essential for myelination and the efficient functioning of the nervous system, and play a role in other neurological disorders, such as multiple sclerosis and Alzheimer’s disease, where myelin damage or loss can lead to impaired nerve function. This new therapy could lead to possible treatments for these and other neurological disorders.
If you would like to keep track of this study and learn more, please visit clinicaltrials.gov and search for the information below, or follow this Direct Study Link.
Sponsor: Myrtelle Inc.
Information Provided By: Myrtelle Inc. (Responsible Party)
Last Update Posted: 2025-11-14
[1] Leone, P., Lober, R.M., Francis, J. et al. Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1/2 trial. Nat Med (2025). https://doi.org/10.1038/s41591-025-03919-w